Jasmine J Han1, Thomas H Beltran2, John W Song3, John Klaric2, Y Sammy Choi4. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Womack Army Medical Center, Fort Bragg, North Carolina. 2. Department of Clinical Investigation, Womack Army Medical Center, Fort Bragg, North Carolina. 3. Department of Medicine, Womack Army Medical Center, Fort Bragg, North Carolina. 4. Department of Medicine, Womack Army Medical Center, Fort Bragg, North Carolina4Department of Pediatrics, Womack Army Medical Center, Fort Bragg, North Carolina.
Abstract
IMPORTANCE: Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HPV vaccination coverage is low in the United States. OBJECTIVES: To estimate the prevalence of genital HPV infection and the HPV vaccination rate in the United States among adult men and to examine potential risk factors for HPV infection. DESIGN, SETTING, AND PARTICIPANTS: The National Health and Nutrition Examination Survey (NHANES) samples a representative cross-section of the US population. Men aged 18 to 59 years were examined in mobile examination centers during the NHANES 2013-2014. DNA was extracted from self-collected penile swab specimens, and HPV genotyping was performed by polymerase chain reaction amplification. Demographic and vaccination information was gathered via self-report during home-based standardized interviews. Binary multivariable logistic regression was used to estimate the odds of HPV infection. MAIN OUTCOMES AND MEASURES: The prevalence of genital HPV infection and the HPV vaccination coverage rate among adult men. RESULTS: During the NHANES 2013-2014, a total of 1868 men aged 18 to 59 years were examined. The overall genital HPV infection prevalence was 45.2% (95% CI, 41.3%-49.3%). The infection prevalence with at least 1 high-risk HPV subtype defined by DNA testing was 25.1% (95% CI, 23.0%-27.3%). In vaccine-eligible men, the prevalence of infection with at least 1 HPV strain targeted by the HPV 4-valent vaccine and HPV 9-valent vaccine was 7.1% (95% CI, 5.1%-9.5%) and 15.4% (95% CI, 11.7%-19.6%), respectively. Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%). CONCLUSIONS AND RELEVANCE: Among men aged 18 to 59 years in the United States, the overall prevalence of genital HPV infection was 45.2% (95% CI, 41.3%-49.3%). The overall genital HPV infection prevalence appears to be widespread among all age groups of men, and the HPV vaccination coverage is low.
IMPORTANCE: Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HPV vaccination coverage is low in the United States. OBJECTIVES: To estimate the prevalence of genital HPV infection and the HPV vaccination rate in the United States among adult men and to examine potential risk factors for HPV infection. DESIGN, SETTING, AND PARTICIPANTS: The National Health and Nutrition Examination Survey (NHANES) samples a representative cross-section of the US population. Men aged 18 to 59 years were examined in mobile examination centers during the NHANES 2013-2014. DNA was extracted from self-collected penile swab specimens, and HPV genotyping was performed by polymerase chain reaction amplification. Demographic and vaccination information was gathered via self-report during home-based standardized interviews. Binary multivariable logistic regression was used to estimate the odds of HPV infection. MAIN OUTCOMES AND MEASURES: The prevalence of genital HPV infection and the HPV vaccination coverage rate among adult men. RESULTS: During the NHANES 2013-2014, a total of 1868 men aged 18 to 59 years were examined. The overall genital HPV infection prevalence was 45.2% (95% CI, 41.3%-49.3%). The infection prevalence with at least 1 high-risk HPV subtype defined by DNA testing was 25.1% (95% CI, 23.0%-27.3%). In vaccine-eligible men, the prevalence of infection with at least 1 HPV strain targeted by the HPV 4-valent vaccine and HPV 9-valent vaccine was 7.1% (95% CI, 5.1%-9.5%) and 15.4% (95% CI, 11.7%-19.6%), respectively. Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%). CONCLUSIONS AND RELEVANCE: Among men aged 18 to 59 years in the United States, the overall prevalence of genital HPV infection was 45.2% (95% CI, 41.3%-49.3%). The overall genital HPV infection prevalence appears to be widespread among all age groups of men, and the HPV vaccination coverage is low.
Authors: Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano Journal: J Infect Dis Date: 2006-09-12 Impact factor: 5.226
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Julie Buchholt Hebnes; Christian Munk; Bugge Nøhr; Ann Nielsen; Hans Ole Jørgensen; Thomas Iftner; Susanne Krüger Kjaer Journal: Sex Transm Dis Date: 2015-08 Impact factor: 2.830
Authors: Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: Anna R Giuliano; Beibei Lu; Carrie M Nielson; Roberto Flores; Mary R Papenfuss; Ji-Hyun Lee; Martha Abrahamsen; Robin B Harris Journal: J Infect Dis Date: 2008-09-15 Impact factor: 5.226
Authors: Catherine C Lerro; Stella Koutros; Gabriella Andreotti; Dale P Sandler; Charles F Lynch; Lydia M Louis; Aaron Blair; Christine G Parks; Srishti Shrestha; Jay H Lubin; Paul S Albert; Jonathan N Hofmann; Laura E Beane Freeman Journal: Cancer Causes Control Date: 2019-02-25 Impact factor: 2.506
Authors: Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey Journal: Proc Natl Acad Sci U S A Date: 2017-12-05 Impact factor: 11.205
Authors: Kate E Dibble; Jessica L Maksut; Elizabeth J Siembida; Morica Hutchison; Keith M Bellizzi Journal: J Adolesc Young Adult Oncol Date: 2019-05-15 Impact factor: 2.223
Authors: Alan G Nyitray; Kayo Fujimoto; Jing Zhao; Anna R Giuliano; John A Schneider; Lu-Yu Hwang Journal: J Infect Dis Date: 2018-02-14 Impact factor: 5.226